Filing Analysis
Regulation FD Disclosure
Filed May 06, 2026
LOW
Lifecore Biomedical, Inc. reported its consolidated financial results for the first quarter ended March 31, 2026, and released an updated investor presentation.
Key Facts
- The company announced Q1 2026 financial results on May 6, 2026.
- A press release detailing the results was furnished as Exhibit 99.1.
- An investor presentation was made available on the company's website and furnished as Exhibit 99.2.
- The report was signed by Chief Financial Officer Ryan D. Lake.
Regulation FD Disclosure
Filed Mar 16, 2026
LOW
Lifecore Biomedical, Inc. announced its financial results for the fourth quarter and transition period ended December 31, 2025, and provided an updated investor presentation.
Key Facts
- Announced Q4 and transition period financial results on March 16, 2026.
- Furnished a press release as Exhibit 99.1.
- Furnished an investor presentation as Exhibit 99.2.
- The transition period ended December 31, 2025.
Other SEC Filing
Filed Mar 05, 2026
LOW
Lifecore Biomedical has scheduled its 2026 Annual Meeting of Stockholders for June 4, 2026, following a change in its fiscal year end to December 31. This shift requires a new deadline of March 16, 2026, for shareholders to submit proposals or director nominations.
Key Facts
- Fiscal year changed from ending the last Sunday of May to December 31, effective for the period ending December 31, 2025.
- 2026 Annual Meeting date set for June 4, 2026.
- The 2025 Annual Meeting was held on October 29, 2025; the new date is more than 30 days from the anniversary of the prior meeting.
- New deadline for shareholder proposals and director nominations is March 16, 2026.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.